Compounds containing 1-((2-(phenylamino)pyridin-4-yl)methyl)urea, their preparation methods and applications

By developing novel KCNQ2/KCNQ3 small molecule opener compounds, the problems of poor selectivity and high adverse reactions of retegabine have been solved, achieving therapeutic effects with higher bioactivity and fewer side effects, and making it suitable for epilepsy, seizures, neuropathic pain and neurodegenerative diseases.

CN123106522APending Publication Date: 2026-11-17SHANGHAI HUILUN BIOLOGICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610657182.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2025-05-14
Filing Date
2026-05-13
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

The existing KCNQ2/KCNQ3 small molecule opener, retigabin, suffers from poor selectivity and high incidence of adverse reactions in clinical applications, which affects its use in the treatment of diseases such as epilepsy and anxiety.

Method used

To develop a novel compound containing 1-((2-(phenylamino)pyridin-4-yl)methyl)urea as a small molecule opener for KCNQ2/KCNQ3, by modifying the structure to improve selectivity and reduce adverse reactions.

Benefits of technology

This compound exhibits higher biological activity, better metabolic stability, and excellent bioavailability, enabling it to effectively treat epilepsy, seizures, neuropathic pain, and neurodegenerative diseases while reducing adverse reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106522A_ABST
    Figure CN123106522A_ABST
Patent Text Reader

Abstract

This invention discloses a compound containing 1-((2-(phenylamino)pyridin-4-yl)methyl)urea, its preparation method, and its application. The compounds of this invention are those represented by general formula (I) or pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R, R', Q, R1, R2, R3, R... a The definitions of x and y are as described in this specification. The compounds of this invention possess one or more of the following advantages: higher biological activity, better metabolic stability, and superior bioavailability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of medicine, specifically relating to a compound containing 1-((2-(phenylamino)pyridin-4-yl)methyl)urea, its preparation method, and its application as a small molecule opener of KCNQ in disease treatment. Background Technology

[0002] Kv7 potassium channels are a class of voltage-dependent potassium ion channels characterized by low-threshold activation, slow activation, and non-inactivation. There are five family members of Kv7 potassium channels (Kv7.1-Kv7.5). All Kv7 potassium channel members have similar topological structures, consisting of four subunits forming a functional channel, with each subunit containing six transmembrane segments (S1-S6). S4 is the voltage-sensing region, playing a crucial role in sensing changes in membrane potential and controlling conformational changes. S5-S6 are the main components of the channel pore region, representing the primary combination and action area of ​​potassium channel openers. Kv7.1 potassium channels are a non-neuronal pathway distributed in peripheral tissues and expressed in the heart to mediate myocardial Iks; mutations in Kv7.1 can lead to Long QT syndrome. Kv7.2-Kv7.5 potassium channels are fundamental to neuronal M-currents, widely distributed throughout the nervous system, and possess various physiological activities. Mutations in the Kv7.2 and Kv7.3 potassium channel genes can lead to various epileptic phenotypes, such as benign familial neonatal convulsions (BFNC), which fully demonstrates the role of M-currents in regulating neuronal excitability. Kv7.4 potassium channels are highly expressed in the outer hair cells of the cochlea and auditory nucleus of the brainstem; mutations in these channels may lead to hereditary deafness. Kv7.5 potassium channels are highly expressed in skeletal muscle and the brain; mutations in these channels may lead to retinopathy. Many diseases, such as epilepsy, anxiety, and deafness, share the common characteristic of hyperexcitability of the membrane. As the molecular basis of M-currents, Kv7 potassium channels can open by sensing changes in membrane potential, upregulating inhibitory potassium currents and thus controlling membrane excitability. This makes Kv7 potassium channels crucial in pain and mental illnesses characterized by hyperexcitability of the nervous system.

[0003] Retigabine is a drug used to treat epilepsy and is currently approved for marketing in the UK, Germany, and Denmark. Studies have confirmed that retigabine's effects are related to voltage-gated potassium channels (KCNQs), with its main mechanism of action being the regulation of M-type potassium currents through action on KCNQ2 / KCNQ3 channels.

[0004] Retigabine (RTG) was the first Kv7 potassium channel opener to be marketed in 2011 for adjunctive treatment of adult partial-onset epilepsy. In addition to its antiepileptic effects, RTG can also be used to treat anxiety disorders, neuralgia, and neurodegenerative diseases. RTG effectively reduces or prevents seizures in various epilepsy models. RTG has shown effective antiepileptic effects against tonic seizures induced by maximal electroshock (MES) and clonic seizures induced by PTZ. Furthermore, RTG can also prevent seizures induced by N-methyl-D-aspartate (NMDA), penicillin, picrotoxin, and kainicacid (KA). The burnout model is suitable for screening various antiepileptic drugs, and RTG is more effective in this model than in other models. Due to its broad action on all Kv7 potassium channel members and other channels, RTG has poor selectivity, which suggests potential adverse effects. Numerous studies have reported a high incidence of adverse events related to the central nervous system (CNS) with retigabine, including dizziness, fatigue, aphasia, speech disorders, and balance disturbances. Other adverse reactions include kidney and urinary tract diseases such as kidney stones and urinary retention, cardiac arrest, and transient non-sustained ventricular tachycardia, as well as retinal discoloration and blue / purple pigmentation of the skin and nails. On April 26, 2013, the FDA's Drug Safety Committee disclosed that retigabine can cause pigmentary reactions in clinical use, including blue skin and retinal pigment changes, but the specific mechanism of action is unclear. The committee recommended that all patients taking this drug undergo regular eye examinations. GlaxoSmithKline (GSK), the original manufacturer, voluntarily withdrew it from the market in 2017 for commercial reasons.

[0005] Therefore, it is necessary to develop novel KCNQ2 / KCNQ3 small molecule openers. Summary of the Invention

[0006] This invention provides a compound of formula (I), its stereoisomer, or a pharmaceutically acceptable salt thereof.

[0007]

[0008] in:

[0009] Ring A and ring B are each independently selected from C 6-14 Aryl or 5-6-membered heteroaryl, wherein the 5-6-membered heteroaryl contains one, two, or three nitrogen atoms;

[0010] L is selected from -NH-, -O-, -S-, -C(O)-, or CR. c R d ;

[0011] R c and Rd Each element is independently selected from hydrogen, halogen, hydroxyl, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl or C 1-6 Halogenated alkoxy groups;

[0012] R is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, -S(O)2R a or -OR e The C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups, optionally surrounded by one or more groups selected from halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl or C 1-6 Substituents of haloalkoxy groups;

[0013] R e Selected from C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups;

[0014] R ’ Each is independently selected from halogens, C 1-6 Alkyl, C 1-6 Alkoxy;

[0015] R a Selected from hydrogen, C 1-6 alkyl;

[0016] Q is selected from key, -Q1-Q2-;

[0017] Q1 is selected from the bond, -CH2-;

[0018] Q2 is selected from key, -CR f R g -;

[0019] R f and R g Each is independently selected from hydrogen, hydroxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkyl groups;

[0020] R1 is selected from C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-12Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-12 heteroaryl, wherein C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 aryl and 5-12 heteroaryl groups, optionally substituted by one or more R 1-1 replace;

[0021] R 1-1 Selected from halogen, hydroxyl, cyano, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups;

[0022] R2 and R3 are each independently selected from hydrogen, C, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl; the C 1-6 Alkyl groups are optionally C 1-6 Alkoxy or C 1-6 Halogenated alkoxy groups;

[0023] Alternatively, any two Rs can be connected to form a C. 3-6 cycloalkyl or 3-6 membered heterocyclic groups, wherein the C 3-6 The cycloalkyl group and the 3-6 membered heterocyclic group are optionally selected from one or more halogens, hydroxyl groups, oxo groups, C-groups, etc. 1-6 Alkyl or C 1-6 Substituents of alkoxy groups;

[0024] Or, R1 and R a The linkage forms a 3-6 membered heterocyclic group, wherein the 3-6 membered heterocyclic group is optionally bonded by one or more elements selected from halogens, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl or C 1-6 Substituents of haloalkoxy groups;

[0025] x is selected from 1, 2, or 3;

[0026] y is selected from 1, 2 or 3.

[0027] In a preferred embodiment of the present invention, the compounds described above are represented by general formula (II-1) or general formula (II-2):

[0028]

[0029] in:

[0030] R4 is selected from hydrogen, halogen, cyano, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl or C 1-6 Halogenated alkoxy groups;

[0031] R5 is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 2-6 alkenyl, C 1-6 Hydroxyalkyl, -S(O)2R a -OR e The C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups, optionally surrounded by one or two groups selected from halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Substituents of haloalkyl groups;

[0032] R6 is selected from hydrogen, halogens, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups;

[0033] R7 is selected from hydrogen, halogen, cyano, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups;

[0034] R8 is selected from hydrogen, halogen, cyano, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups;

[0035] R9, R 10 and R 11 Each is independently selected from hydrogen, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl group. In a preferred embodiment of the invention, R4 mentioned above is selected from halogens, cyano groups, and C6 groups. 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 alkyl.

[0036] In a preferred embodiment of the present invention, R5 mentioned above is selected from C. 3-6 Cycloalkyl, 3-8 membered heterocyclic groups, C 2-4 alkenyl, C 1-3 Hydroxyalkyl, -S(O)2R a -OR e The C 3-6Cycloalkyl groups and 3-8-membered heterocyclic groups, optionally selected by one or two halogens, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 The alkyl halogroup is substituted by a substituent.

[0037] In a preferred embodiment of the present invention, R6 mentioned above is selected from hydrogen, halogen, and C. 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkyl groups.

[0038] In a preferred embodiment of the present invention, R7 mentioned above is selected from hydrogen, halogen, cyano, and C. 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkyl groups.

[0039] In a preferred embodiment of the present invention, R8 mentioned above is selected from hydrogen, halogen, and C. 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkyl groups.

[0040] In a preferred embodiment of the present invention, R9 and R mentioned above are described in the present invention. 10 and R 11 Each is independently selected from hydrogen, halogen, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkyl groups.

[0041] In a preferred embodiment of the present invention, the R described above... a Selected from hydrogen or C 1-3 alkyl.

[0042] In a preferred embodiment of the present invention, Q is selected from bond, -Q1-Q2-; Q1 is selected from bond, -CH2-; Q2 is selected from bond, -CR f R g -;R f and R g Each is independently selected from hydrogen, hydroxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkyl groups.

[0043] In a preferred embodiment of the present invention, R1 mentioned above is selected from C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic, phenyl, 5-12 membered heteroaryl; the C 3-10Cycloalkyl, 3-10-membered heterocyclic, phenyl, and 5-12-membered heteroaryl groups, optionally with one or more R 1-1 replace.

[0044] In a preferred embodiment of the present invention, the R described above... 1-1 Selected from halogens, hydroxyl groups, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups.

[0045] In a preferred embodiment of the present invention, R2 and R3 mentioned above are each independently selected from hydrogen and C. 1-3 Alkyl, C 1-3 Hydroxyalkyl, the C 1-3 Alkyl groups are optionally C 1-3 Halogenated alkoxy or C 1-3 Halogenated alkoxy groups.

[0046] In a preferred embodiment of the present invention, the R described above... e Selected from C 1-3 Alkyl, C 1-3 Haloalkyl, C 3-4 Cycloalkyl or 3-4 membered heterocyclic groups.

[0047] In a preferred embodiment of the present invention, R5 and R8, as described above, together with the atoms connected to them, form C. 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups.

[0048] In a preferred embodiment of the present invention, R7 and R8, as described above, together with the atoms connected to them, form C. 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups.

[0049] In a preferred embodiment of the present invention, R6 and R7, as described above, together with the atoms connected to them, form C. 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups.

[0050] In a preferred embodiment of the present invention, R4 and R6, as described above, together with the atoms connected to them, form C. 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups.

[0051] In a preferred embodiment of the present invention, the present invention described , .

[0052] In a preferred embodiment of the present invention, R4 mentioned above is selected from hydrogen, fluorine, chlorine, cyano, -CF3, methoxy, methyl, ethyl, ethoxy, and -CH2CF3.

[0053] In a preferred embodiment of the present invention, R5 mentioned above is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ... , .

[0054] In a preferred embodiment of the present invention, R6 mentioned above is selected from hydrogen, fluorine, and chlorine.

[0055] In a preferred embodiment of the present invention, R7 mentioned above is selected from hydrogen, fluorine, chlorine, methoxy, and cyano.

[0056] In a preferred embodiment of the present invention, R8 mentioned above is selected from hydrogen, fluorine, and chlorine.

[0057] In a preferred embodiment of the present invention, the L mentioned above is selected from -NH-, -O-, -S-, -CH2-, -CF2-, and -C(O)-.

[0058] In a preferred embodiment of the present invention, R9 and R mentioned above are described in the present invention. 10 and R 11 Each is independently selected from hydrogen, fluorine, and chlorine.

[0059] In a preferred embodiment of the present invention, R2 and R3 mentioned above are each independently selected from hydrogen, methyl, ethyl, .

[0060] In a preferred embodiment of the present invention, Q is selected from bond, -Q1-Q2-; Q1 is selected from bond, -CH2-; Q2 is selected from bond, -CH2-, -CH(CF3)-, -CH(OH)-.

[0061] In a preferred embodiment of the present invention, R1 mentioned above is selected from... Cyclopropyl , , , , , , , , , , Optional by one or two R 1-1 replace.

[0062] In a preferred embodiment of the present invention, the R described above... 1-1 Selected from -CF3, methyl, -CHF2, fluorine, methoxy, cyclopropyl, chlorine, phenyl, cyclohexyl, and hydroxyl.

[0063] In a preferred embodiment of the present invention, R1 mentioned above is selected from... , , , , , , , .

[0064] In a preferred embodiment of the present invention, the compound described above is represented by general formula (III):

[0065]

[0066] in:

[0067] M1 is CH or N;

[0068] R4 and R7 are independently halogenated and C. 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy or C 1-3 Halogenated alkoxy groups;

[0069] R2 and R3 are each independently hydrogen or C. 1-3 Alkyl, C 1-3 Haloalkyl, CH2-C 1-3 Alkoxy or CH2-C 1-3 Halogenated alkoxy groups;

[0070] Q represents a bond or -Q1-Q2-; Q1 is selected from bond, -CH2-; Q2 is selected from bond, -CH2-, -CH(CF3)-, -CH(OH)-;

[0071] R1 is Cyclopropyl The Cyclopropyl Optional R 1-1 replace;

[0072] R 1-1 It can be -CF3, methyl, -CHF2, fluorine, methoxy, cyclopropyl or chlorine.

[0073] In a preferred embodiment of the present invention, in the general formula (III) described above, R4 and R7 are each independently chlorine or fluorine.

[0074] In a preferred embodiment of the present invention, in the general formula (III) described above, R2 and R3 are each independently hydrogen or methyl.

[0075] In a preferred embodiment of the present invention, in the general formula (III) described above, Q is a bond or .

[0076] In a preferred embodiment of the present invention, in the general formula (III) described above, R1 is...

[0077] In a preferred embodiment of the present invention, in the general formula (III) described above, -Q-R1 is...

[0078] In a preferred embodiment of the present invention, the compounds described above are selected from the compounds shown in Table 1:

[0079] Table 1

[0080]

[0081]

[0082]

[0083]

[0084]

[0085] .

[0087] In another aspect, the present invention provides a pharmaceutical composition comprising:

[0088] (1) The compounds described above in this invention or their pharmaceutically acceptable salts, and

[0089] (2) Pharmaceutically acceptable excipients.

[0090] The present invention also provides the use of the compound of Formula I described above or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition described above, in the preparation of a medicament for the prevention and / or treatment of KCNQ2 / KCNQ3 mediated conditions; preferably, the conditions are selected from epilepsy, seizures, neuropathic pain, acute ischemic stroke, and neurodegenerative diseases.

[0091] The compounds of the present invention have one or more advantages, including higher biological activity, better metabolic stability, and superior bioavailability.

[0092] Terminology Explanation

[0093] Unless otherwise stated, the terms used in the specification and claims have the following meanings.

[0094] The term "oxo" refers to =O, where an oxygen atom replaces two hydrogen atoms on the same carbon atom; that is, a carbonyl group replaces a methylene group.

[0095] The term "thio(group)" refers to =S, where a sulfur atom replaces two hydrogen atoms on the same carbon atom.

[0096] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight-chain or branched group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 8 carbon atoms, more preferably an alkyl group containing 1 to 6 carbon atoms, and most preferably an alkyl group containing 1 to 3 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, etc., and their various branched isomers.

[0097] The term "alkenyl" refers to an alkyl group as defined above, consisting of at least two carbon atoms and at least one carbon-carbon double bond, such as vinyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc.

[0098] The term "cycloalkyl" refers to a saturated or partially saturated monocyclic or polycyclic cyclic hydrocarbon substituent, wherein the cycloalkyl ring contains 3 to 12 carbon atoms, preferably 3 to 10 carbon atoms. Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclohepttrienyl, cyclooctyl, etc. Polycyclic cycloalkyl groups include spirocyclic alkyl, bridged cycloalkyl, and fused cycloalkyl groups. Non-limiting examples of polycyclic cycloalkyl groups include: wait.

[0099] The term "heterocyclic group" refers to a saturated or partially saturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, and S, but excluding the -OO-, -OS-, or -SS- ring moieties, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, it contains 3 to 8 ring atoms. In this invention, "membered" indicates the number of ring atoms, such as a 3-8 membered heterocyclic group indicating that it contains 3-8 ring atoms. Non-limiting examples of monocyclic heterocyclic groups include oxetane, thiohepane, azirone, tetrahydropyranyl, azironeheptane, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, dihydroimidazolidinyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl, etc., preferably oxetane, thiohepane, azirone, tetrahydrofuranyl, tetrahydropyranyl, 1-aminoethylene-1-oxothiran, azironeheptane, piperidinyl, piperazinyl, etc. Polycyclic heterocyclic groups include spirohepane, fused heterocyclic, or bridged heterocyclic groups. Non-limiting examples of polycyclic heterocyclic groups include: wait.

[0100] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., a ring sharing adjacent carbon atom pairs) group having a conjugated π-electron system, preferably 6- to 10-membered, such as phenyl and naphthyl. Phenyl is more preferred.

[0101] The term "heteroaryl" refers to a heteroaryl system comprising 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, and nitrogen. The heteroaryl is preferably a 5-8 member mono-heteroaryl or an 8-10 member di-heteroaryl, more preferably a 5-membered mono-heteroaryl, 6-membered mono-heteroaryl, 8-membered di-heteroaryl, 9-membered bicyclic heteroaryl, or 10-membered bicyclic heteroaryl, such as imidazolyl, furanyl, thienyl, thiazolyl, pyrazolyl, pyrroleyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperazinyl, thienopyrroleyl, thiazonopyrroleyl, oxazolopyrroleyl, furanylpyrroleyl, thienoylfuranyl, oxazoloimidazolyl, thiazonofuranyl, thiadiazoloimidazolyl, oxazoloimidazolyl, thienothiazolyl, etc. The heteroaryl ring may be fused to an aryl, heterocyclic, or cycloalkyl ring, wherein the ring attached to the parent structure is a heteroaryl ring. Non-limiting examples include: wait.

[0102] The term "alkoxy" refers to -O- (alkyl) and -O- (unsubstituted cycloalkyl), where alkyl is defined as described above. Non-limiting examples of alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, and cyclohexoxy. Alkoxy groups can be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl, or carboxylic acid ester group.

[0103] "Halogenated alkyl" refers to an alkyl group substituted with one or more halogens, wherein the alkyl group is as defined above. Non-limiting examples include trifluoromethyl and difluoromethyl.

[0104] "Haloalkoxy" refers to an alkoxy group that has been substituted by one or more halogens, wherein the alkoxy group is as defined above.

[0105] "Hydroxyalkyl" refers to an alkyl group substituted with a hydroxyl group, wherein the alkyl group is as defined above. Non-limiting examples include: -CH2OH, -C(CH3)2(OH).

[0106] The different terms such as “X is selected from A, B, or C”, “X is selected from A, B, and C”, “X is A, B, or C”, and “X is A, B, and C” all express the same meaning, that is, X can be any one or more of A, B, and C.

[0107] The " on the substituent of the present invention" "" indicates the position where the substituent is attached to the site being substituted.

[0108] "Optional" or "optionally" means that the event or environment described below may but does not have to occur, and the description includes the possibility or absence of such event or environment. For example, "optionally alkyl-substituted heterocyclic group" means that the alkyl group may but does not have to be present, and the description includes cases where the heterocyclic group is substituted with an alkyl group and cases where the heterocyclic group is not substituted with an alkyl group.

[0109] "One or more" means 1, 2, 3, 4, 5, 6, 7, 8, 9 or more, preferably 1, 2, 3 or 4.

[0110] "Pharmaceutical composition" means a mixture containing one or more of the compounds described herein or their physiologically / pharmacologically acceptable salts or prodrugs, along with other chemical components, such as physiologically / pharmacologically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to a living organism, thereby promoting the absorption of the active ingredient and the exertion of its biological activity.

[0111] "Pharmaceutical acceptable" means relatively non-toxic, safe, and suitable for patient use.

[0112] "Pharmaceutically acceptable salt" refers to a salt obtained by reacting a compound with a pharmaceutically acceptable acid or base. When a compound contains a relatively acidic functional group, a base addition salt can be obtained by contacting the compound with a sufficient amount of a pharmaceutically acceptable base in a suitable inert solvent.

[0113] When a compound contains a relatively basic functional group, an acid addition salt can be obtained by contacting the compound with a sufficient amount of pharmaceutically acceptable acid in a suitable inert solvent. See Handbook of Pharmaceutical Salts: Properties, Selection, and Use (P. Heinrich Stahl, Camille G. Wermuth, 2011, 2nd Revised Edition).

[0114] Unless otherwise specified, all technical and scientific terms used herein have the standard meaning in the field to which the claimed subject matter pertains. Where multiple definitions exist for a term, the definition herein shall prevail.

[0115] Unless otherwise stated, the chiral compounds in this invention can be synthesized from chiral raw materials or resolved by chiral column chromatography as is common in the art.

[0116] Based on common knowledge in the field, the above-mentioned preferred conditions can be combined arbitrarily to obtain various preferred embodiments of the present invention.

[0117] The reagents and raw materials used in this invention are commercially available or prepared by methods disclosed in the prior art.

[0118] Unless otherwise specified, the chiral carbon in the compounds of this invention is in the R configuration, S configuration, or a racemic mixture of the compound.

[0119] In this invention, each definition is based on the premise that it does not violate the principles of chemical bonding.

[0120] General preparation method of this invention:

[0121] Method 1:

[0122]

[0123] Among them: R1, Q, R4, R5, R6, R7, R8, R9, R 10 and R 11 The definition is as described above in this invention.

[0124] Method 2:

[0125]

[0126] Among them: R1, Q, R4, R5, R6, R7, R8, R9, R 10 and R 11 The definition is as described above in this invention.

[0127] Method 3:

[0128]

[0129] Among them: R1, Q, R4, R5, R6, R7, R8, R9, R 10 and R 11 The definition is as described above in this invention. Detailed Implementation

[0130] The present invention is further illustrated below by way of examples, but these examples do not limit the invention to the scope of the embodiments described. Experimental methods in the following examples, unless otherwise specified, were performed according to conventional methods and conditions, or as selected in the product instructions. Unless otherwise specified, the reagents used in the present invention are commercially available or prepared by methods disclosed in the prior art.

[0131] Example 1: Synthesis of Compound 1

[0132]

[0133] Step 1: Synthesis of Compounds 1-2

[0134] To a solution of 2-chloro-6-iodoaniline (2 g, 7.89 mmol, 1.0 equiv) in 1,4-dioxane (30 mL), cyclopropylboronic acid (1.02 g, 11.84 mmol, 1.5 equiv), palladium acetate (177.2 mg, 0.789 mmol, 0.1 equiv), 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl (752.3 mg, 1.58 mmol, 0.2 equiv), and potassium phosphate (5.02 g, 23.67 mmol, 3.0 equiv) were added at room temperature. The reaction mixture was heated to 100 °C under nitrogen protection. o C and stirred for 16 hours. After the reaction was complete, the mixture was concentrated and water (50 mL) was added. The mixture was then extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography in ethyl acetate / petroleum ether (50%) to give compounds 1-2 as yellow solids (410.0 mg, 31.06%).

[0135] LCMS: (ESI, m / z): 168.2 [M+H] + .

[0136] Step 2: Synthesis of compounds 1-3

[0137] In a microwave tube, 2-bromo-4-cyanopyridine (327 mg, 1.795 mmol, 1.5 equiv), tris(dibenzylacetone)dipalladium (110 mg, 0.119 mmol, 0.1 equiv), 4,5-bis(diphenylphosphine-9,9-dimethyloxanthracene) (138 mg, 0.239 mmol, 0.2 equiv), and cesium carbonate (1.17 g, 3.59 mmol, 3.0 equiv) were added to a 1,4-dioxane (3 mL) solution of compounds 1-2 (200.0 mg, 1.197 mmol, 1.0 equiv). The reaction mixture was heated to 110 °C under nitrogen protection. oC and stirred for 16 hours. After the reaction was complete, the mixture was concentrated and water (20 mL) was added. The mixture was then extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography in dichloromethane / petroleum ether (50%) to give a yellow solid compound 1-3 (65 mg, 20.5%).

[0138] LCMS: (ESI, m / z): 270.1 [M+H] + .

[0139] Step 3: Synthesis of compounds 1-4

[0140] To a solution of compounds 1-3 (65.0 mg, 0.24 mmol, 1.0 equiv) in methanol (5 mL) and ammonia (0.5 mL) at room temperature, Raney nickel (10.0 mg) was added. The reaction mixture was stirred at room temperature for 2 hours under a hydrogen atmosphere. After the reaction was complete, the reaction mixture was filtered through filter paper, and the filtrate was concentrated to give a white solid, compound 1-4 (33.0 mg, yield 50.4%).

[0141] LCMS: (ESI, m / z): 274.1 [M+H] + .

[0142] Step 4: Synthesis of Compound 1

[0143] At room temperature, N,N'-carbonyldiimidazole (22 mg, 0.132 mmol, 1.1 equiv) and N,N-diisopropylethylamine (78 mg, 0.6 mmol, 5.0 equiv) were added to a solution of compounds 1-4 (33 mg, 0.12 mmol, 1 equiv) in dichloromethane (3 mL), and the reaction mixture was stirred at room temperature for 2 hours. Spiro[3.3]heptane-2-amine hydrochloride (18 mg, 0.12 mmol, 1.0 equiv) was added to the reaction mixture, and the mixture was stirred at room temperature for 16 hours. After the reaction was complete, water (20 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (20 mL x 3). The combined organic layers were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by preparative high-performance liquid chromatography (HPLC) under the following conditions: (Column specifications: Sunfire C18 10 μm, 19 mm * 250 mm; Mobile phase A: water (0.1% formic acid), Mobile phase B: acetonitrile; Flow rate: 20 mL / min; Elution gradient: 31–33% B for 16 min; Detection wavelength: UV 254 nm / 214 nm; Retention time (min): 7.4–10), yielding compound 1 (17.18 mg, yield 34.9%).

[0144] LCMS: (ESI, m / z): 411.3 [M+H] + .

[0145] 1 H NMR (400 MHz, DMSO-d6) δ8.27 (s, 1H), 7.83 (d, J = 5.2 Hz, 1H), 7.30 – 7.28 (m, 1H), 7.18 – 7.14 (m, 1H), 6.87 – 6.85 (m, 1H), 6.46 (d, J =5.2 Hz, 1H), 6.34 (s, 1H), 6.27 – 6.20 (m, 2H), 4.06 (d, J = 6.0 Hz, 2H), 3.93 – 3.83 (m, 1H), 2.27 – 2.22 (m, 2H), 1.99 – 1.92 (m, 3H), 1.89 – 1.85(m, 2H), 1.80 – 1.69 (m, 4H), 0.83 – 0.79 (m, 2H), 0.62 – 0.58 (m, 2H).

[0146] Example 2 Synthesis of Compound 2

[0147]

[0148] Referring to the synthesis method of compound 1, using replace Compound 2 (15.36 mg, yield 25.12%) was prepared.

[0149] LCMS: (ESI, m / z): 417.2 [M+H] + .

[0150] 1 H NMR (400 MHz, DMSO-d6) δ 8.27 (s, 1H), 7.84 (d, J = 4.8 Hz, 1H), 7.29 (d, J = 7.6 Hz, 1H), 7.18 – 7.14 (m, 1H), 6.86 (d, J = 7.2 Hz, 1H), 6.60(s, 1H), 6.48 (d, J = 5.2 Hz, 1H), 6.38 (s, 1H), 5.95 (s, 1H), 4.74 (s, 1H),4.10 – 4.08 (m, 2H), 3.39 (s, 1H), 3.05 (d, J = 7.2 Hz, 1H), 2.71 – 2.64 (m,1H), 1.98 – 1.93 (m, 1H), 0.84 (s, 9H), 0.81 (d, J = 1.2 Hz, 2H), 0.62 – 0.59(m, 2H).

[0151]

[0152]

[0153]

[0154] Biological testing evaluation

[0155] Example 1: Detection of the effect of the compound of the present invention on stably overexpressed KCNQ2 / KCNQ3 channels using FLIPR potassium flow technology.

[0156] 1. Test compound: Homemade compound

[0157] 2. Information on experimental reagents and instruments

[0158] 2.1 Reagent Information

[0159]

[0160] 2.2 Instrument Information

[0161]

[0162] 3. Test Methods

[0163] Cell culture

[0164] The HEK-293 cell line, stably expressing the KCNQ2 / KCNQ3 receptor, was constructed in-house by the laboratory of Beijing Aisiyipu Biotechnology Co., Ltd., and its gene information is as follows:

[0165] KCNQ2: NM_172107; KCNQ3: NM_004519;

[0166] 1) Digest and collect cells, count them, and then seed the cells in black-bottomed 384-well plates and culture them overnight.

[0167] 2) Prepare 1× Assay buffer and 1× Chloride-free assay buffer according to the kit instructions. At the same time, prepare 2× dyes with 1× Assay buffer for later use.

[0168] 3) Invert the plate and centrifuge to remove the culture medium from the 384-well plate. Immediately add 20 μL of 1 × Assay buffer.

[0169] 4) Take 20 μL of the dye prepared in step 2 and add it to the corresponding experimental well. Incubate at 37°C in the dark for 1 hour.

[0170] 5) Using 3 mM TI + Prepare 5× positive compounds using 1× Chloride-free assay buffer and transfer 30 μL to the corresponding 384 source plate.

[0171] After the test substance is incubated, 10 μL of the test substance prepared in step 5 is added to the test well using a FLIPR instrument. Data is collected and recorded for 5 minutes. The excitation light for potassium flow detection is 470-495 nm, and the emission light is 515-575 nm.

[0172] 4. Data Analysis

[0173] 1) Z' factor = 1 - 3 * (SD) High +SD Low ) / (AVE High - AVE Low )

[0174] 2)CV High = (SD High / AVE High ) *100%

[0175] 3)CV Low = (SD Low / AVE Low ) *100%

[0176] 4) S / B = AVE High / AVE Low

[0177] 5) Calculate compound EC using GraphPad nonlinear fitting formula. 50 :

[0178] Y=Bottom + (Top-Bottom) / (1+10^((LogEC 50 -X) ×HillSlope))

[0179]

[0180] The average value of the positive control

[0181] Mean of negative control (DMSO)

[0182] Table 2:

[0183]

[0184] Note: The relative half-maximal effective concentration (EC50) of the compound tested is shown in this paper. 50 Scope definition: A: EC 50 =< 100 nM; B: EC 50 >100 nM and < 500 nM; C: EC 50 >500 nM and < 1000 nM; D: EC 50 >1000 nM.

[0185] Other compounds of the present invention were tested according to the above test plan to obtain the EC values ​​of the compounds of the present invention. 50 The value is in the range of less than 1000 nM; the preferred compound of this invention is EC. 50 Value less than 500 nM; the preferred compound of the present invention is EC. 50 The value is less than 100 nM.

[0186] Experimental results show that the compound of this invention has good KCNQ2 / 3 agonist activity.

[0187] Example 2: The effects of the compounds of this invention on KCNQ2 / KCNQ3 potassium channels were studied using manual patch-clamp technique.

[0188] 1. Test substance: The compound prepared in this invention;

[0189] 2. Reagent and Instrument Information

[0190] 2.1 Reagent and Instrument Information

[0191]

[0192] 2.2 Reagent Information

[0193]

[0194] 3. Compound preparation

[0195] Weigh an appropriate amount of the test sample. Calculate the required DMSO volume using the formula: DMSO volume = actual compound mass × content (purity) / (molecular weight × theoretical concentration). Take the corresponding volume of DMSO, dissolve the test sample, and weigh the DMSO simultaneously. Calculate the volume using the solvent density to ensure accurate dosage. Calculate the actual stock solution concentration based on the final DMSO usage. The calculated stock solution concentration will generally differ slightly from the planned concentration. This process is automatically completed by the Aisiyipu compound preparation table. If solubility issues arise, the stock solution concentration will be adjusted. The entire preparation process should be conducted in the dark.

[0196] For the highest detectable concentration of the test substance, the stock solution is directly diluted with extracellular fluid or further diluted with DMSO. Other concentrations are first diluted sequentially with DMSO from high to low concentration to create intermediate diluents, which are then further diluted with extracellular fluid to the working solution concentration. The concentration of DMSO in each working solution does not exceed 0.1%. Before patch-clamp testing, the working solution of the test substance is sonicated for 20 min in the dark.

[0197] 4. Cell Culture

[0198] This study used the HEK-293 cell line, which stably expresses the KCNQ2 / KCNQ3 receptor, and was constructed by the laboratory of Beijing Aisiyipu Biotechnology Co., Ltd. The gene information is as follows:

[0199] KCNQ2: NM_172107; KCNQ3: NM_004519;

[0200] 4.1. HEK-293 cell lines stably expressing KCNQ2 / KCNQ3 receptors were cultured in DMEM medium containing 10% fetal bovine serum and 800 µg / mL G418 at 37°C and 5% carbon dioxide.

[0201] 4.2. Cell Passaging: Remove the old culture medium and wash once with PBS, then add 1 mL of 0.25% Trypsin-EDTA solution and incubate at 37°C for about 1 min. When the cells detach from the bottom of the dish, add about 5 mL of preheated (37°C) complete culture medium. Gently pipette the cell suspension to separate the aggregated cells. Transfer the cell suspension to a sterile centrifuge tube and centrifuge at 1000 rpm for 5 min to collect the cells. For expansion or maintenance culture, seed the cells in 6 cm cell culture dishes at a density of 2.5 × 10⁶ cells per dish. 5 100 cells (final volume: 5 mL).

[0202] 4.3 To maintain the electrophysiological activity of cells, the cell density must not exceed 80%.

[0203] 4.4 Before manual patch-clamp detection, cells were separated using 0.25% Trypsin-EDTA, and 8 × 10⁸ cells were used. 3 The cells were seeded onto a coverslip and cultured in a 24-well plate (final volume: 500 µL). After 18 hours, the cells were analyzed.

[0204] 4.5 Before automated patch-clamp detection, cells were separated using TrypLE™ Express, digestion was stopped by adding culture medium, centrifuged, resuspended, and counted. The cell density was adjusted to 2-3 × 10⁻⁶ cells / year. 6 Cells / mL were collected, and then the cells were gently mixed on a balanced shaker for 15-20 min at room temperature before being analyzed.

[0205] All operations follow the standard operating procedures for cell culture of Beijing Aisiyipu Biotechnology Co., Ltd.

[0206] 5 Electrophysiological Recording

[0207] 5.1 Record the liquids used

[0208] 1) Extracellular fluid: KCNQ-001-1

[0209] 140mM NaCl, 5mMKCl, 1mMMgCl2·6H2O, 2mM CaCl2·2H2O, 10mM HEPES, 5mMD-Glucose, NaOH adjust pH=7.4.

[0210] 2) Intracellular fluid: KCNQ-001-2

[0211] 120 mM K-Aspartic, 20 mM KCl, 1 mM MgCl2·6H2O, 5 mM HEPES, 10 mM EGTA, 5mM Mg-ATP, KOH adjust pH=7.2.

[0212] Extracellular fluid was stored at 4°C for 2 weeks. Intracellular fluid was prepared, aliquoted into 1 mL tubes, and stored at -20°C. Freshly thawed intracellular fluid was used daily for experiments. All intracellular fluid was used within three months; otherwise, it was discarded and reconstituted.

[0213] 5.2 Patch clamp testing

[0214] The voltage stimulation protocol for whole-cell patch-clamp recording of KCNQ2 / KCNQ3 potassium currents is as follows: After whole-cell sealing, the cell membrane voltage is clamped at -80 mV. The clamping voltage is depolarized from -110 mV to +40 mV in 10 mV steps and maintained for 3 s. The mean steady-state current is used for IV curve analysis. Then, recording is continued for 500 ms at -30 mV (Protocol-1) and 0 mV (Protocol-2), and the tail current peak is used for activation curve analysis.

[0215] (Protocol-1)

[0216] (Protocol-2)

[0217] 5.3 Manual Patch Clamp

[0218] The manual patch-clamp procedure begins by using a microelectrode puller to draw a glass capillary into a recording electrode. The electrode, filled with intracellular fluid, is then placed into a microelectrode holder. A coverslip containing cells is placed in a recording bath under an inverted microscope. Under the microscope, the microelectrode manipulator is used to immerse the electrode in the extracellular fluid, and the electrode resistance (Rpip) is recorded. The electrode is then slowly brought into contact with the cell surface, and negative pressure is applied to create a GΩ high-resistance seal. Fast capacitance compensation is then performed, and negative pressure is continued to rupture the cell membrane, establishing a whole-cell recording mode. Finally, slow capacitance compensation is performed, and experimental parameters such as series resistance (Rs) are recorded. No leakage compensation is applied. Experimental data are acquired by an EPC 10 amplifier (HEKA) and stored in PatchMaster (HEKA) software.

[0219] Once the current amplitude stabilized in the control extracellular solution, drug administration began. Each drug concentration was recorded repeatedly until the current stabilized before measuring the next concentration. Blank control extracellular solution and the working solution of the test compound were administered to the cells sequentially from low to high concentration via gravity perfusion in the recording bath, while a peristaltic pump was used for fluid replacement during recording. The current detected in each cell in extracellular solution without the compound served as its control group. All electrophysiological experiments were performed at room temperature.

[0220] 5.4 Automatic Patch Clamp

[0221] When performing electrophysiological assays using the fully automated patch-clamp QPatch 48X (Sophion) device, the prepared cells are first placed on the centrifuge of the Qpatch workbench and washed using multiple centrifugation / resuspension methods to replace the cell culture medium with extracellular fluid. An MTP-96 plate is removed and placed in the MTP source position. The QPlate chip is removed and placed in the QPlatesource position. The robotic arm scans the barcodes on the MTP-96 plate and the QPlate chip and picks it up to the measurement station. Intracellular fluid and extracellular fluid are aspirated from the liquid pools and added to the intracellular fluid pool and cell and compound pool of the QPlate chip, respectively. At the measurement station, all measurement sites on the QPlate undergo initial quality control. The quality control process includes aspirating the cell suspension from the centrifuge's cell container and positioning the cells onto the chip wells using a pressure controller to establish a high-resistance seal, forming a whole-cell recording mode. Once a stable control current baseline is obtained, the test substances are sequentially aspirated from the MTP-96 plate according to their concentration and applied to the cells.

[0222] Each drug concentration was designed for multiple administration. Blank control solution and working solution of the test compound were applied to the cells sequentially from low to high concentrations. The current detected in each cell in the solution without the compound served as its control group. All electrophysiological experiments were performed at room temperature.

[0223] 6 Data Analysis

[0224] First, a current-voltage (IV) curve was plotted for each concentration, with voltage on the horizontal axis and normalized steady-state current on the vertical axis. The relative current magnitudes of each compound concentration at -30 mV were compared, and the increase factor of the current amplitude (Icompound) after each concentration was calculated relative to the control current amplitude (Icontrol), i.e., Potency% = (Icompound / Icontrol) * 100%. Data are expressed as Mean ± SE. Then, the EC50 value of the compound's agonist effect was calculated using the Hill equation, and a nonlinear fit was performed on the concentration-effect curve, i.e., Y = 1 / (1 + 10^((LogEC50 - X) * HillSlope)), where X is the logarithm of the concentration, Y is the Potency%, and EC50 is the half-maximal effective concentration.

[0225] The activation curve is fitted using the Boltzmann equation, I / Imax = 1 / (1 + exp((V1 / 2 - Vm) / к)), where I / Imax is the normalized tail current, V1 / 2 is the half-maximal activation voltage, Vm is the test voltage, and к is the slope factor affecting the slope of the activation curve. The maximum shift in V1 / 2 for each compound concentration is calculated using ΔV1 / 2 = V1 / 2 test - V1 / 2 control. The shift EC is then calculated by fitting a concentration-effect curve based on the change in shift amplitude with compound concentration. 50 value.

[0226] Curve fitting and graphical analysis were both performed using GraphPad Prism software.

[0227] EC50 of compounds 1, 2, 5, 8, 103, 107, and 109 of this invention were measured. 50 Values ​​less than 100 nM, EC values ​​of compounds 36, 101, and 102 50 The value is greater than 500 nM and less than or equal to 1000 nM.

[0228] Experimental results show that the compound of this invention has good KCNQ2 / KCNQ3 agonist activity.

[0229] Test Example 3: Study on the pharmacokinetic behavior of the compound of the present invention in mice.

[0230] Experimental reagents: The compounds of this invention, prepared in-house.

[0231] Experimental plan:

[0232] Three healthy male ICR mice (SPF grade, source: Beijing Vital River Laboratory Animal Technology Co., Ltd.), weighing 18-25 g, were administered 1 mg / kg of the compound intravenously at a volume of 5 ml / kg. The compound was prepared using 5% DMSO + 10% Solutol + 85% Saline (w / v). The animals were not fasted before the experiment.

[0233] Three healthy male ICR mice (SPF grade, source: Beijing Vital River Laboratory Animal Technology Co., Ltd.), weighing 18-25 g, were administered the compound at a dose of 5 mg / kg by gavage at a volume of 10 ml / kg. The compound was prepared using 5% DMSO + 10% Solutol + 85% Saline (w / v). The animals were not fasted before the experiment.

[0234] Blood samples were collected via buccal sampling at 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h after intravenous administration and at the same time after gavage administration. Approximately 0.05 mL of blood was collected per sample. Heparin sodium was used for anticoagulation. Blood samples were placed on ice and centrifuged within 1 hour to separate the plasma (centrifugation conditions: 6000g, 3 min, 2-8ºC). The concentration of compounds in the plasma was determined by liquid chromatography-tandem mass spectrometry. Plasma samples were stored at -80ºC before analysis. Pharmacokinetic parameters were calculated using PhoenixWinNonlin 8.2.0 based on the blood drug concentration data at different time points.

[0235] Experimental results show that the compound of the present invention has low clearance rate, high plasma exposure, and good oral bioavailability in rodent ICR mice, and has good pharmacokinetic properties.

Claims

1. A compound of formula (I), its stereoisomer, or a pharmaceutically acceptable salt thereof, in: Ring A and ring B are each independently selected from C 6-14 Aryl or 5-6-membered heteroaryl, wherein the 5-6-membered heteroaryl contains one, two, or three nitrogen atoms; L is selected from -NH-, -O-, -S-, -C(O)-, or CR. c R d ; R c and R d Each element is independently selected from hydrogen, halogen, hydroxyl, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl or C 1-6 Halogenated alkoxy groups; R is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, -S(O)2R a or -OR e The C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups, optionally surrounded by one or more groups selected from halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl or C 1-6 Substituents of haloalkoxy groups; R e Selected from C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups; R ’ Each is independently selected from halogens, C 1-6 Alkyl, C 1-6 Alkoxy; R a Selected from hydrogen, C 1-6 alkyl; Q is selected from key, -Q1-Q2-; Q1 is selected from the bond, -CH2-; Q2 is selected from key, -CR f R g -; R f and R g Each is independently selected from hydrogen, hydroxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkyl groups; R1 is selected from C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-12 heteroaryl, wherein C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 aryl and 5-12 heteroaryl groups, optionally substituted by one or more R 1-1 replace; R 1-1 Selected from halogen, hydroxyl, cyano, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups; R2 and R3 are each independently selected from hydrogen, C, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl; the C 1-6 Alkyl groups are optionally C 1-6 Alkoxy or C 1-6 Halogenated alkoxy groups; Alternatively, any two Rs can be connected to form a C. 3-6 cycloalkyl or 3-6 membered heterocyclic groups, wherein the C 3-6 The cycloalkyl group and the 3-6 membered heterocyclic group are optionally selected from one or more halogens, hydroxyl groups, oxo groups, C-groups, etc. 1-6 Alkyl or C 1-6 Substituents of alkoxy groups; Or, R1 and R a The linkage forms a 3-6 membered heterocyclic group, wherein the 3-6 membered heterocyclic group is optionally bonded by one or more elements selected from halogens, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl or C 1-6 Substituents of haloalkoxy groups; x is selected from 1, 2, or 3; y is selected from 1, 2 or 3.

2. The compound according to claim 1, its stereoisomers, or pharmaceutically acceptable salts thereof, characterized in that, The compounds are shown as general formula (II-1) or general formula (II-2): in: R4 is selected from hydrogen, halogen, cyano, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl or C 1-6 Halogenated alkoxy groups; R5 is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 2-6 alkenyl, C 1-6 Hydroxyalkyl, -S(O)2R a -OR e The C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups, optionally surrounded by one or two groups selected from halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Substituents of haloalkyl groups; R6 is selected from hydrogen, halogens, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups; R7 is selected from hydrogen, halogen, cyano, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups; R8 is selected from hydrogen, halogen, cyano, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups; R9, R 10 and R 11 Each is independently selected from hydrogen, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups.

3. The compound, its stereoisomer, or a pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that, It meets one or more of the following conditions: (1) R4 is selected from halogen, cyano, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 alkyl; (2) R5 is selected from C 3-6 Cycloalkyl, 3-8 membered heterocyclic groups, C 2-4 alkenyl, C 1-3 Hydroxyalkyl, -S(O)2R a -OR e The C 3-6 Cycloalkyl groups and 3-8-membered heterocyclic groups, optionally selected by one or two halogens, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Substituents of haloalkyl groups; (3) R6 is selected from hydrogen, halogens, and C. 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkyl groups; (4) R7 is selected from hydrogen, halogen, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkyl groups; (5) R8 is selected from hydrogen, halogens, and C. 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkyl groups; (6) R9, R 10 and R 11 Each is independently selected from hydrogen, halogen, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkyl groups; (7) R a Selected from hydrogen or C 1-3 alkyl; (8) Q is selected from key, -Q1-Q2-; Q1 is selected from key, -CH2-; Q2 is selected from key, -CR f R g -;R f and R g Each is independently selected from hydrogen, hydroxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkyl groups; (9) R1 is selected from C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic, phenyl, 5-12 membered heteroaryl; the C 3-10 Cycloalkyl, 3-10-membered heterocyclic, phenyl, and 5-12-membered heteroaryl groups, optionally with one or more R 1-1 replace; (10) R 1-1 Selected from halogens, hydroxyl groups, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups; (11) R2 and R3 are each independently selected from hydrogen and C. 1-3 Alkyl, C 1-3 Hydroxyalkyl, the C 1-3 Alkyl groups are optionally C 1-3 Halogenated alkoxy or C 1-3 Halogenated alkoxy groups; (12) R e Selected from C 1-3 Alkyl, C 1-3 Haloalkyl, C 3-4 Cycloalkyl or 3-4 membered heterocyclic groups.

4. The compound according to claim 1 or 2, its stereoisomer, or a pharmaceutically acceptable salt thereof, characterized in that, It meets one or more of the following conditions: (1) R5 and R8, together with the atoms attached to them, form C. 3-6 cycloalkyl groups, 3-6 membered heterocyclic groups; (2) R7 and R8, together with the atoms attached to them, form C. 3-6 cycloalkyl groups, 3-6 membered heterocyclic groups; (3) R6 and R7, together with the atoms attached to them, form C3-6 cycloalkyl groups and 3-6 membered heterocyclic groups; (4) R4 and R6 together with the atoms attached to them form C3-6 cycloalkyl groups and 3-6 heterocyclic groups.

5. The compound, its stereoisomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1-3, characterized in that, It meets one or more of the following conditions: (1) R4 is selected from hydrogen, fluorine, chlorine, cyano, -CF3, methoxy, methyl, ethyl, ethoxy, -CH2CF3; (2) R5 is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, , , , , , , , , , , ; (3) R6 is selected from hydrogen, fluorine, and chlorine; (4) R7 is selected from hydrogen, fluorine, chlorine, methoxy, and cyano; (5) R8 is selected from hydrogen, fluorine, and chlorine; (6) L is selected from -NH-, -O-, -S-, -CH2-, -CF2-, -C(O)-; (7) R9, R 10 and R 11 Each is independently selected from hydrogen, fluorine, and chlorine; (8) R2 and R3 are each independently selected from hydrogen, methyl, ethyl, , , ; (9) Q is selected from bond, -Q1-Q2-; Q1 is selected from bond, -CH2-; Q2 is selected from bond, -CH2-, -CH(CF3)-, -CH(OH)-; (10) R1 is selected from Cyclopropyl , , , , , , , , , , , -CF3 , phenyl, , , , , , , , , , , , or The Cyclopropyl , , , , , , , , , , , phenyl, , , , , , , , , , , , , and Optional by one or two R 1-1 replace; (11) R 1-1 Selected from -CF3, methyl, -CHF2, fluorine, methoxy, cyclopropyl, chlorine, phenyl, cyclohexyl, and hydroxyl.

6. The compound, its stereoisomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1-5, characterized in that, R1 is selected from , , , , , , , , , , , , , , , , , , , -CF3 , , , , , , , , , , , , , , , , , , , , , , , , , , , , .

7. The compound according to claim 1, its stereoisomers, or pharmaceutically acceptable salts thereof, characterized in that, The compound is shown in general formula (III): in: M1 is CH or N; R4 and R7 are independently halogenated and C. 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy or C 1-3 Halogenated alkoxy groups; R2 and R3 are independently hydrogen and C, respectively. 1-3 Alkyl, C 1-3 Haloalkyl, CH2-C 1-3 Alkoxy or CH2-C 1-3 Halogenated alkoxy groups; Q represents a bond or -Q1-Q2-; Q1 is selected from bond, -CH2-; Q2 is selected from bond, -CH2-, -CH(CF3)-, -CH(OH)-; R1 is Cyclopropyl , or The Cyclopropyl , and Optional R 1-1 replace; R 1-1 It can be -CF3, methyl, -CHF2, fluorine, methoxy, cyclopropyl or chlorine.

8. The compound, its stereoisomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1-7, characterized in that, The compounds are selected from those shown in Table 1.

9. A pharmaceutical composition comprising: (1) The compound of any one of claims 1-8 or a pharmaceutically acceptable salt thereof, and (2) Pharmaceutically acceptable excipients.

10. The use of a compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1-8, or a pharmaceutical composition as described in claim 9, in the preparation of a medicament for the prevention and / or treatment of KCNQ2 / KCNQ3-mediated conditions; preferably, the conditions are selected from epilepsy, seizures, neuropathic pain, acute ischemic stroke, and neurodegenerative diseases.